Study: Age at time of Type 2 diabetes or hypertension diagnosis linked to glaucoma
September 08, 2022
Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Therapeutic Glaucoma
Study focuses on technology to unveil optical texture and trajectories of the axonal fiber bundles on retina
September 12, 2022
A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.
Bausch + Lomb, Sanoculis announce strategic agreements to address unmet needs in glaucoma
July 29, 2022
Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.
Selecting the right topical glaucoma therapy is important
July 22, 2022
Janet B. Serle, MD, discusses the pros and cons of various treatment options.
Nicox’s NCX 470 Dolomites Phase 2 results published in Journal of Glaucoma
April 11, 2022
NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470
Travoprost intracameral implant shows efficacy in topical form
April 05, 2022
Device demonstrates potential as a durable, sustained-release glaucoma therapy
iSTAR Medical continues market expansion with first MINIject® surgeries in the UK
April 04, 2022
The company announced the expansion of its commercial rollout of its MIGS implant to the UK
Graybug Vision announces pipeline expansion
March 30, 2022
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.
Glaucoma Research Foundation honored Vanderbilt’s David Calkins, PhD, with 2022 President’s Award at annual gala
March 25, 2022
Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.